SK-MEL-19Homo sapiens (Human)Cancer cell line
Also known as: AL-Mel, SKMEL19, Sk Mel19, SK-Mel19, SK-MEL19, SkMEL-19, SKMEL-19, SK-Mel-19
No AI-generated summary available for this cell line.
Basic Information
| Database ID | CVCL_6025 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Not specified |
Donor Information
| Age | 50 |
|---|---|
| Age Category | Adult |
| Sex | Male |
Disease Information
| Disease | Cutaneous melanoma |
|---|---|
| Lineage | Skin |
| Subtype | Cutaneous Melanoma |
| OncoTree Code | SKCM |
DepMap Information
| Source Type | Academic lab |
|---|---|
| Source ID | ACH-002005_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Asn131Lys (c.393C>A) | Unspecified | - | Unknown |
| MutationSimple | CDKN2A | p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T) | Unspecified | - | PubMed=9598804 |
| MutationSimple | BRAF | p.Val600Glu (c.1799T>A) | Unspecified | - | PubMed=26214590 |
| Gene deletion | CDKN2B | - | Homozygous | - | PubMed=35933914 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.
Rosen N., Solit D.B.
Cancer Res. 74:2340-2350(2014).
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF.
Wolchok J.D., Houghton A.N., Solit D.B.
Oncogene 31:446-457(2012).
Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.
Ostrer H., Osman I.
Cancer Res. 71:2561-2571(2011).
Frequent p16-independent inactivation of p14ARF in human melanoma.";
Bishop D.T., Bastian B.C., Newton-Bishop J.A., Polsky D.
J. Natl. Cancer Inst. 100:784-795(2008).
Genomic profiling of malignant melanoma using tiling-resolution arrayCGH.
Guldberg P., Borg A.
Oncogene 26:4738-4748(2007).
Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Fountain J.W.
Genes Chromosomes Cancer 22:157-163(1998).
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.
Houghton A.N., Eisinger M., Albino A.P., Cairncross J.G., Old L.J.
J. Exp. Med. 156:1755-1766(1982).
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines.
Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.
J. Natl. Cancer Inst. 66:1003-1012(1981).
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
Old L.J.
Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980).
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma.
Old L.J.
J. Exp. Med. 158:53-65(1983).
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity.
Dracopoli N.C., Houghton A.N., Old L.J.
Proc. Natl. Acad. Sci. U.S.A. 82:1470-1474(1985).
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.
Meyer zum Buschenfelde K.-H.
Proc. Natl. Acad. Sci. U.S.A. 86:2804-2808(1989).
Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA.
Bouchard B., Fuller B.B., Vijayasaradhi S., Houghton A.N.
J. Exp. Med. 169:2029-2042(1989).
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells.
Old L.J.
Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976).
Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens.
Shiku H., Takahashi T., Oettgen H.F., Old L.J.
J. Exp. Med. 144:873-881(1976).
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
Fogh J., Wright W.C., Loveless J.D.
J. Natl. Cancer Inst. 58:209-214(1977).
Malignant melanoma. Current status of the search for melanoma-specific antigens.
Houghton A.N., Oettgen H.F., Old L.J.
(In book chapter) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston; USA (1981).